Related Experiment Video
Updated: Jan 11, 2026

Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation
Published on: December 15, 2017
Recent developments in biomarker guided therapy for Crohn's disease
André Bargas1, Joana Torres1,2,3, Bram Verstockt4,5
1Division of Gastroenterology, Surgical Department, Hospital Beatriz Ângelo, Loures, Portugal.
Biomarkers are crucial for advancing precision medicine in Crohn's disease (CD). Current research reviews serologic, genetic, and other markers, highlighting the need to overcome implementation barriers for better CD patient care.
Area of Science:
- Gastroenterology and Immunology
- Translational Medicine
- Biomarker Discovery
Background:
- Crohn's disease (CD) is a chronic inflammatory condition with unpredictable progression and treatment response.
- The expanding therapeutic options necessitate reliable biomarkers for diagnosis, risk stratification, and treatment guidance.
- Current management of CD often lacks the precision afforded by validated biomarkers.
Purpose of the Study:
- To review the current landscape of biomarker development and application in Crohn's disease.
- To critically evaluate various types of biomarkers (serologic, genetic, transcriptomic, proteomic, epigenetic) across different disease stages.
- To identify limitations and barriers hindering the clinical implementation of biomarkers in CD.
Main Methods:
- Comprehensive literature review of biomarker research in Crohn's disease.
- Critical appraisal of evidence for different classes of biomarkers.
- Analysis of challenges in clinical translation and implementation.
Main Results:
- Significant advances in biomarker discovery across multiple 'omic' platforms.
- Evidence for serologic, genetic, transcriptomic, proteomic, and epigenetic markers exists but requires further validation.
- Major hurdles remain in clinical implementation, including cost, standardization, and regulatory issues.
Conclusions:
- Precision medicine in CD is currently limited by the lack of validated, deployable biomarkers.
- A shift from biomarker discovery to implementation is essential, integrating them into clinical trials and practice.
- Overcoming barriers to biomarker validation and adoption is critical for improving Crohn's disease management.
More Related Videos
09:08Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies
Published on: June 2, 2021
10:21Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin
Published on: September 12, 2019
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...